Clinical and dosimetric correlation in terms of treatment response, bladder and rectal toxicities in cervical cancer patients treated with cobalt 60 high dose rate brachytherapy

PeerJ. 2024 Aug 22:12:e17759. doi: 10.7717/peerj.17759. eCollection 2024.

Abstract

Background: High dose rate (HDR) image-guided brachytherapy with Cobalt-60 isotope is a relatively recent approach. The aim of the study is to evaluate the clinical and dosimetric parameters in terms of tumour response, bladder, and rectal toxicity in patients undergoing Co-60 HDR brachytherapy.

Materials and method: All patients were initially treated with chemoradiation (CT-RT) at our center or other referral centers with external beam radiation therapy (EBRT) for a dose of 45 Gy-60 Gy at 1.8-2Gy/fraction (including nodal boost) with concomitant chemotherapy with either cisplatin or carboplatin. Patients were then scheduled for brachytherapy within 1 week after completion of CT-RT and are assessed by local examination. Depending on local examination parameters at the time of brachytherapy they were eligible either for intracavitary brachytherapy (ICBT) or interstitial brachytherapy (ISBT).

Results: The complete response (CR) observed in stage I, II, III, IVA were 60%, 79.4%, 86% and 76.2% respectively. Complete response was seen in patients with mean EQD2 of 78.67 Gy10, 83.33 Gy10, 84.23 Gy10, 85.63 Gy10 in stages I, II, III, IVA respectively. 79.2% of cisplatin-treated patients and 87.5% of carboplatin-treated patients had a complete response indicating that patients treated with either chemotherapy had similar response rates.

Conclusions: According to results obtained from the study we conclude by saying that higher rates of complete response to treatment in cervical cancer is seen in patients with shorter overall treatment time (OTT), shorter interval between end of definitive CT-RT and beginning of brachytherapy and squamous cell histology. The study also noted the trend of increasing mean EQD2 to tumor with increasing stage for achieving complete response. Higher acute bladder and rectal toxicity is seen in patients who received EQD2 of ¿70-90Gy3 and ¿70Gy3 respectively. The study findings suggest that the clinical outcomes and the toxicities are clinically comparable with other radioisotope based HDR brachytherapy treatment.

Keywords: Co60 Brachytherapy; Dosimetric correlation; EQD2; HDR Brachytherapy; OTT.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Brachytherapy* / adverse effects
  • Brachytherapy* / methods
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Carboplatin / therapeutic use
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / methods
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Cobalt Radioisotopes* / adverse effects
  • Cobalt Radioisotopes* / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Radiation Injuries / etiology
  • Radiotherapy Dosage*
  • Rectum / diagnostic imaging
  • Rectum / pathology
  • Rectum / radiation effects
  • Treatment Outcome
  • Urinary Bladder* / drug effects
  • Urinary Bladder* / pathology
  • Urinary Bladder* / radiation effects
  • Uterine Cervical Neoplasms* / drug therapy
  • Uterine Cervical Neoplasms* / pathology
  • Uterine Cervical Neoplasms* / radiotherapy

Substances

  • Cobalt Radioisotopes
  • Cobalt-60
  • Cisplatin
  • Carboplatin
  • Antineoplastic Agents

Grants and funding

The authors received no funding for this work.